Document is current
Any future updates will be listed below
-
Authors
Garcia‑Saenz, Jose Angel https://orcid.org/0000-0001-6880-0301
Lopez-Barajas, Isabel Blancas
Echavarria, Isabel
Gonzalez, Carmen Hinojo
Vila, Mireia Margeli
Antón, Fernando Moreno
Pernas, Sonia
Cajal, Teresa Ramon y
Ribelles, Nuria
Ezquerra, Meritxell Bellet
- License Information
-
More Information
Article History
Received: 5 October 2025
Accepted: 7 October 2025
First Online: 3 November 2025
Declarations
:
: Jose Angel Garcia‑Saenz has received speaker fees and has attended an advisory board for Novartis, Lilly, Daiichi Sankyo, and Gilead; has attended an advisory board for AstraZeneca, Pierre Fabre, and EISAI; has received a grant from Seagen; has received speaker fees from Roche, Asofarma, and Exact Sciences; and has received a grant and has attended an advisory board for Stemline Menarini. Isabel Blancas Lopez-Barajas has received speaker fees and grants and has attended an advisory board for Roche, Lilly, and AstraZeneca; has received speaker fees and has attended an advisory board for Novartis, Celgene, Eisai, Pierre Fabre, BMS, Daiichi Sankyo, Grünenthal, Seagen, and Veracyte; and has received a grant from Agendia. Isabel Echavarria has received speaker fees and has attended an advisory board for Lilly; has received speaker fees from Pfizer, Novartis, Roche, and Pierre Fabre; and has attended an advisory board for AstraZeneca. Mireia Margeli Vila has attended an advisory board for Gilead, Lilly, Piere Fabre, Daiichi Sankyo, and Eisai; has received a grant from Pfizer; and has received speaker fees from Pierre Fabre. Fernando Moreno Antón has received speaker fees, grants, and other fees and has attended an advisory board for Pfizer; has attended an advisory board for Novartis, Daiichi Sankyo, and AstraZeneca; and has received other fees from MSD, Pierre Fabre, Gilead, Seagen, and Roche. Sonia Pernas has received speaker fees and non-financial support and has attended an advisory board for AstraZeneca and Daiichi Sankyo; has received grants and has attended an advisory board for Roche; has received speaker fees and non-financial support from Lilly and Novartis; has attended an advisory board for Pierre Fabre and Seagen; has received non-financial support Gilead; has received non-financial support and has attended an advisory board for Pfizer; and has received speaker fees from Eisai. Meritxell Bellet Ezquerra has received speaker fees from Pfizer, Lilly, and Novartis; has attended an advisory board for Pfizer, Lilly, Novartis, and Stemline Menarini; and has received travel expenses from Pfizer. Carmen Hinojo Gonzalez, Teresa Ramon y Cajal, and Nuria Ribelles declare that they have no conflicts of interest.
: Not applicable. The manuscript does not contain clinical studies or patient data.
